East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Ketorolac Tromethamine Ophthalmic Solution, 0.5%. Aurobindo Pharma’s Ketorolac Tromethamine Ophthalmic Solution, 0.5% are an AB-rated generic equivalent to the reference listed drug (RLD), Acular® Ophthalmic Solution, 0.5% (Allergan, Inc.)

Ketorolac Tromethamine Ophthalmic Solution is indicated for:

• Temporary relief of ocular itching due to seasonal allergic conjunctivitis
• Treatment of postoperative inflammation in patients who have undergone cataract extraction.